Highlights from AAHFN 2026
Featured
Acoramidis Achieves Long-Term Disease Stabilization in People with Transthyretin Amyloid Cardiomyopathy
Continuous use of transthyretin (TTR) stabilizer acoramidis reduced the risk of all-cause mortality and cardiovascular disease-related mortality and achieved durable disease stabilization in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) who continued treatment up to 54 months, according to long-term data from the ATTRibute-CM study.
June 29 2026
Read moreRelated Articles
Red Flag Screening Tool May Facilitate Earlier Detection of Transthyretin Amyloid Cardiomyopathy
An automatic screening tool that can be integrated into electronic health records (EHRs) may prompt providers to elevate their index of suspicion for transthyretin amyloid cardiomyopathy (ATTR-CM) in patients presenting with heart failure, leading to earlier initiation of diagnostic testing and therapeutic interventions in this population, according to an analysis presented at the 2026 Annual Meeting of the American Association of Heart Failure Nurses in San Diego, California.
June 29 2026
Read moreIs a History of Substance Use Disorder a Disqualifier for Heart Transplantation?
Patients with heart failure who need a heart transplant undergo extensive assessment, including psychosocial evaluation, to determine whether the survival and recovery potential weighs in their favor. While active substance use disorder has been cited as a temporary contraindication or, at the very least, a reason for caution in listing a patient as a heart transplant candidate [López-Azor JC. Eur Heart J Qual Care Clin Outcomes 2026; 12:134-135], transplant considerations are not simple yes or no questions.
June 29 2026
Read morePatient Education Reduced Early Readmissions for Heart Failure
Empowering patients with heart failure to manage their own health and optimize their treatment regimens after discharge from the hospital is an effective way to reduce early hospital readmission for heart failure, according to findings from an academic medical center, presented at the 2026 Annual Meeting of the American Association of Heart Failure Nurses in San Diego, California.
June 29 2026
Read moreOutpatient Heart Failure Programs Up the Game in Cardiac Rehabilitation
Intensive outpatient programs designed to help patients discharged from the hospital after acute heart failure events successfully reduced early hospital readmission rates through frequent follow-ups, targeted interventions, and nurse-led education, according to data presented at the 2026 Annual Meeting of the American Association of Heart Failure Nurses (AAHFN 2026) in San Diego, California.
June 30 2026
Read moreNurse-Led Protocol Improves Early Progressive Mobility for Patients with Heart Failure
An analysis presented at the 2026 Annual Meeting of the American Association of Heart Failure Nurses (AAHFN 2026) in San Diego, California, showed that mobility rounding led by inpatient nurses promoted early mobility and decreased length of stay for patients hospitalized for acute heart failure episodes.
June 30 2026
Read moreReview of Patient Charts Reveals Suboptimal Adherence to Heart Failure Therapies
Polypharmacy and medication class may influence adherence to the medications prescribed for heart failure, which remains generally inadequate, according to a retrospective review presented at the 2026 Annual Meeting of the American Association of Heart Failure Nurses in San Diego, California.
Jun 30, 2026
Read moreAI-Enabled Monitoring of Peripheral Edema May Improve Prevention of Heart Failure Events
A home monitoring device powered by artificial intelligence (AI) reduced recurrent heart failure events and readmissions compared to the standard of care, providing more actionable information than conventional monitoring, according to preliminary findings from the HEARTFELT study, presented at the 2026 Annual Meeting of the American Association of Heart Failure Nurses in San Diego, California.
July 1 2026
Read moreMisread Clinical Signals Perpetuate Disparities in Heart Failure Care
Breakthroughs in pharmacology and minimally invasive devices have reshaped the landscape of heart failure care, with dozens of targeted therapies achieving disease stabilization and improved survival in this vulnerable population. But one look through the dual lens of heart failure care is all it takes to understand that those benefits do not reach all patients in equal measure, according to Melvin Echols, MD, associate professor at the Morehouse School of Medicine in Atlanta, Georgia and Chief Diversity, Equity, and Inclusion Officer at the American College of Cardiology.
July 1 2026
Read moreDisease Stabilization Translates into Slower Functional Decline for Patients with Transthyretin Amyloid Cardiomyopathy
Early and continuous treatment with transthyretin (TTR) stabilizer acoramidis led to significant improvements in health status and slower functional decline in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM), according to data presented at the 2026 Annual Meeting of the American Association of Heart Failure Nurses (AAHFN 2026) in San Diego, California.
July 1 2026
Read more
© 2026 Wolters Kluwer. All right reserved.